A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Obinutuzumab; Tazemetostat
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 17 Feb 2017 Treatment table amended:- Tazemetostat added as combination treatment, number of treatment arms changed from 2 to 5, patient number changed from 46 to 92, Parallel assignment added to trial design.
    • 01 Jul 2016 Planned End Date changed from 1 Oct 2017 to 1 May 2019.
    • 01 Jul 2016 Planned primary completion date changed from 1 Oct 2017 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top